Results 221 to 230 of about 247,626 (282)
Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome
Objectives VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani +10 more
wiley +1 more source
Spatial Deconstruction of the Plasma Membrane. [PDF]
Mandala VS +5 more
europepmc +1 more source
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley +1 more source
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar +6 more
wiley +1 more source
Species level composition of Faecalibacterium spp. in the gut of Japanese adults revealed by rpoA-based sequencing analysis. [PDF]
Ang A +4 more
europepmc +1 more source
Definitions of ‘medicines use’ and ‘polypharmacy’ may refer to all medicines, regular long‐term medicines or another subset. Valid definitions of medicines use should incorporate type of use (long term, short course and as needed [PRN]), changes in use (start, stop and dose change) and a description of temporal examination (cross‐sectional or ...
Lorna Pairman, Paul Chin, Matthew Doogue
wiley +1 more source
Engineering a light-controllable fluorescent protein for peroxynitrite detection <i>via</i> genetic code expansion. [PDF]
Roman Arocho GM +5 more
europepmc +1 more source
Smoking status and the efficacy of remote ischaemic conditioning: a secondary analysis of the RICAMIS trial. [PDF]
Zhang XW, Cui Y, Chen HS.
europepmc +1 more source

